You are viewing an incomplete version of our website. Please click to reload the website as full version.

CASP2 and RIPK1 Domain Containing Adaptor with Death Domain (CRADD) (C-Term) Peptide

Details for Product No. ABIN1381972, Supplier: Log in to see
Protein Name
  • cradd
  • MGC89035
  • zgc:101717
  • CRADD
  • DKFZp468A2219
  • LOC100226369
  • raidd
  • MGC78788
  • MRT34
  • RAIDD
Protein Region
C-Term
Origin
Human
3
2
2
Application
Blocking Peptide (BP)
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Blocked Antibody anti-CRADD antibody (CASP2 and RIPK1 Domain Containing Adaptor with Death Domain) (C-Term) (ABIN1030612)
Characteristics 19 amino acids near the carboxy terminus of human RAIDD.
Human
Research Area Cancer, Apoptosis/Necrosis
Application Notes RAIDD peptide is used for blocking the activity of RAIDD.
Restrictions For Research Use only
Format Liquid
Concentration 200 μg/mL
Buffer PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1 % bovine serum albumin and 0.02 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Expiry Date 12 months
Background publications Duan, Dixit: "RAIDD is a new 'death' adaptor molecule." in: Nature, Vol. 385, Issue 6611, pp. 86-9, 1997 (PubMed).

Dragic, Litwin, Allaway et al.: "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5." in: Nature, Vol. 381, Issue 6584, pp. 667-73, 1996 (PubMed).

Deng, Liu, Ellmeier et al.: "Identification of a major co-receptor for primary isolates of HIV-1." in: Nature, Vol. 381, Issue 6584, pp. 661-6, 1996 (PubMed).